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1014-62 Comparison of Novel Strategy Therapies for 
Obstructive Hypertrophic Cardiomyopathy: Relation of 
Relief of Left Ventricular Outflow Obstruction to 
Improved Symptoms and Health-Related Quality of Life 
Parameters 
Saidi Mohiddin. Gina Rowe, Londa Hathaway, Eric Leifer, Nancy Leidy, Susan Biddle, 
Sue Marden, Dorothy Tripodi, Lameh Fananapazir, National Institutes of Health, 
Bethesda, MD 
Background: Left ventricular (LV) ouHlow obstruction is present in about a third of 
patients with hypertrophic cardiomyopathy (HCM), and may cause disabling symptoms. 
Alcohol septal ablation (ASA) and dual chamber (DDD) pacing have been proposed as 
alternative therapies tc cardiac surgery for relief of LV outflow obstruction. Methods: We 
compared the impact of ASA and DDD on LV gradient, symptoms and health-related 
quality of life (HRQL) in a randomized propective study involving 70 patients with 
obstructive HCM and drug-refractory symptoms. The demographic and clinical character- 
istics of the 2 arms were similar. Patients completed the SF-36 Health Survey and a 
symptom measure at baseline (prior to randomization), 3 and 6 months. Results: Both 
procedures significantly reduced the LV ouHlow gradients determined at cardiac cathter- 
ization: ASA arm, the mean (SD)gradient reduced from 105 (32) mm Hg to 33 (32) mm 
Hg [a change of 72 (37) mm Hg, or 69%; and DDD arm, from 101 (36) mmHg to 49 (39) 
mm Hg (a change of 51 (32) mm Hg, or 50%]. ASA resulted in significantly (about 20 mm 
Hg) greater reduction in LV gradient, p=O.O17. Of the 70 patients randomized. 32 DDD 
and 29 ASA were available for HRQL analysis. Both therapies resulted in significant and 
equal improvement in all symptom and HRQL outcomes from baseline to 3 months, with 
no further change at 6.month follow-up. There was no significant correlation between 
changes in symptoms or HRQL and reductions in LV gradients, perhaps due to the 
dynamic nature of the LV ouHlow obstruction. Conclusions: (1) ASA and DDD are both 
effectwe in relieving LV obstruction in most patients; and 2) both DDD and ASA are asso- 
ciated with significant symptom and HRQL benefits at 3 months that persist to 6 months. 
As the symptomatic and HRQL benefits were equivalent, DDD pacing should perhaps be 
tried first. ASA may then be performed in patients with residual obstruction and symp- 
toms without ccncerns about Inducing heart block. 
1014-63 Septal Ablation for Symptomatic Hypertrophic 
Obstructive Cardiomyopathy: An Analysis of the 
Patients With Dissatisfactory Intervention Results 
Lothar Faber -I Dirk Welge, Peer Ziemssen. Hubert Seggewiss, Dieter Fassbender, Dieter 
Horstkotte. Heart Center North Rhine-Westphalia, Bad Oeynhausen, Germany, 
Leopoldina Hospital, Schwemfurt, Germany 
Background: In 90% of the patients (pts). with symptomatic hypertrophic obstructive 
cardiomyopathy (HOCM) the outilow gradient (LVOTG) can significantly be reduced or 
removed by septal ablation (PTSMA). Pts. with a dissatisfactory LVOTG response are 
not yet characterized sufficiently. 
Results: From 279 pts. reevaluated 3 months after PTSMA, 36 (13%) had PTSMA fail- 
ure (PF) defined as a less than 50% LVOTG reduction. On average, these pts. were 
younger (50*16 vs. 54*14 years; pcO.Ol), had a thicker septum (22+4 vs. 20&4 mm; 
pcO.O5), a higher baseline LVOTG (69*33 vs. 56233 mm Hg; p<O.Ol). and a lower CK 
release after PTSMA (477*228 vs. 556*272U/l; p<O.O5). 
The main cause for PF was an insufficient PTSMA lesion on PD-echo at follow-up (n=22; 
successful re-PTSMA in 6 pts.. surgery in 1 pt. and spontaneous LVOTG reduction in 6 
pts. within the following 12 months). Suboptimal scar localization, observed in 7 pts. 
treated before routine echocardiographic guidance (MCE) for PTSMA and requiring a re- 
PTSMA in 4 pts. and surgery in 2 pt., was not seen with MCE-guidance any more. 
Another group of pts. with PF showed persisting SAM and LVOTG despite a sufficient 
PTSMA scar due to excessive elongation of the mitral leaflets (n=5; spontaneous LVOTG 
elimination in one of them within 12 months). One pt. each had coexistent fibromuscular 
subaortic stenosis and severe midcavity obstruction which both did not respond tc 
PTSMA. 
Conclusions: Even with MCE guiding, younger pts. with a thicker septum, and those 
with markedly elongated mitral leaflets seem to be less suitable for PTSMA. Further- 
more. LVOTG elimination may need up to 1 year. Pre-interventional pt. selection, 
echocardiographic assessment, and pt. information should take these findings into con- 
sideration. 
1014-64 Prevalence and Spectrum of Thin Filament Mutations in 
Patients With Hypertrophic Cardiomyopathy: A 
Comprehensive Mutational Analysis of Troponin T, 
Troponin I, Alpha Tropomyosin, and Cardiac Actin 
Sara L. Van Driest, Erik G. Ellsworth, Melissa L. Will, Bernard J. Gersh, Steve R. 
Ommen, Michael J. Ackerman, Mayo Clinic, Rochester, MN 
Background: Thin filament mutations are reported tc cause -20% of Hypertrophic Car- 
diomyopathy (HCM) and display a dwerse phenotype. However, the frequency of these 
mutations and their associated phenotype in a single large cohort have not been 
reported. We determined the prevalence and spectrum of mutations in the genes encod- 
mg the thin filament proteins cardiac troponin T (TNNT2), cardiac troponin I (TNN13), 
alpha tropomyosin (TPMI), and cardiac actin (ACJC) in a large cohort of unrelated HCM 
patients, and searched for defining clinical characteristics for thin filament-HCM. 
Methods: DNA from 395 unrelated patients with HCM was obtained and analyzed. Muta- 
tional analysis of all protein coding excns of TNNTZ (15 exons), TNN13 (6). TPMi (9), 
and ACTC (6) was performed using polymerase chain reaction, denaturing high perfor- 
mance lkquid chromatography, and DNA sequencing. The clinical data ware maintained 
In a database independent of the patient genotype. 
Results: Overall, only 19 patients (4.6%) were identified having 12 distinct thin filament 
mutations: 9 with TNNT2 mutations, 6 with TNN13mutations, 3 with JPMl mutations, 
and 1 with an ACTC mutation. Of the 12 unique missense mutations identified, 6 (67%) 
were novel mutations. As a group. patients with thin filament mutations were not signifi- 
cantly different from the rest of the cohort in age at diagnosis, left ventricular wall thick- 
ness (LVWT), gradient, or family history of HCM or sudden death. However, when 
compared to patients with beta myosin heavy chain mutations (n=54), patients with thin 
filament mutations had less hypertrophy (LVWT = 19.6 f 6 mm versus 24.3 * 6 mm, p= 
0.04). 
Conclusions: This study represents a comprehensive evaluation for mutations in the 
genes encoding the thin filament of the cardiac sarccmere at a large, tertiary referral cen- 
ter for HCM. Here, thin filament mutations were identified in ~5% of the HCM cohort. 
Moreover, except for a lesser degree of hypertrophy when compared to patients with 
thick filament HCM on the basis of mutations in the beta myosin heavy chain, there were 
no cllnical features to distinguish this small subset of thin filament-HCM from HCM due to 
mutations in other genes. 
1014-65 Evidence That Left Ventricular Outflow Tract 
Obstruction Is a Predictor of Outcome in Patients With 
Hypertrophic Cardiomyopathy 
Martin S. Marorr lacopo Olivotto, Sandra Betocchi, Susan A. Casey, Thomas E. 
Gohman. John R. Lesser, Maria A. Losi, France Cecchi, Barry J. Maron, Minneapolis 
Heart Institute Foundation, Minneapolis, MN, Azienda Ospedaliera Careggi, Florence, 
Italy 
Background. One of the most visible and quantifiable features of hypertrophic cardiomy- 
opathy (HCM) has been the left ventricular (LV) ouHlow tract gradient. Major therapeutic 
interventions (such as surgery, alcohol septal ablation and pacing) have been introduced 
to relieve subaortic obstruction and disabling symptoms. However, the significance of LV 
ouHlow obstruction with regard to clinical outcome in HCM has been the subject of con- 
troversey and remains incompletely unresolved. 
Methods. We assessed the impact of LV ouHlow gradient on mortality and morbidity I” a 
large HCM cohort prospectively followed ever 6.3k6.2 years. 
Results. Df 1101 consecutive patients, 127 (12%) died of HCM and 196 (18%) devel- 
oped severe progressive heart failure-related symptoms (NYHA functional classes III/IV): 
at initial evaluation, 273 study patients (25%) had LV outilow obstruction under basal 
conditions with continuous wave Doppler (gradient, =Omm Hg). Probability of HCM- 
related mortality and progression to severe disabling symptoms was significantly greater 
in patients with outilow obstruction than in those without (OR 2.0 and 4.4, respectively; 
pcO.0001 for both end-points), and was most substantial in obstructive patients 2 40 
years old (p<O.OOl). HCM mortality and morbidity due to obstruction did not increase with 
greater magnitude of gradient above the threshold of 30mm Hg. Multivariate analysis 
showed outflow obstruction to be a strong and independent predictor of HCM-mortality 
and severe symptoms (OR 1.6; p=O.O18) among several other disease variables. Likeli- 
hood of sudden death was also greater in patients wth obstruction (OR 1.9; p=O.O14), 
although the positive predictive value for obstruction was low (i.e., only 7%). 
Conclusions. Basal LV outflow obstruction (gradient, ?3Omm Hg) IS a strong and inde- 
pendent predictor of progression to severe symptoms and cardiovascular mortality in 
HCM. Therefore, treatment interventions that reduce outflow gradients can be expected 
to favorably influence quality of life and long-term prognosis in severely symptomatic 
patients with obstructive HCM, and could possibly be justified somewhat earlier at lesser 
gradients than is current practice. 
1014-66 Lefi Atrial Volumetric Remodeling Predicts Functional 
Capacity in Hypertrophic Cardiomyopathy 
Vandana Sachdey Charles W. Birdsall, Dorothy Tripodi, lnez Ernst, Lameh 
Fananapazir, Jonathan F. Plehn, National Heart, Lung and Blood Institute, Bethesda, MD 
Background: Left atrial volumetric remodeling (LAR) is a marker of hypertensive left ven- 
tricular (LV) hypertrophy and associated cardiovascular events and probably represents 
chronic hemodynamic overload. Its role as an indicator of disease severity in primary 
hypertrophic cardiomyopathy (HCM) has not been reported. We, therefore, compared 
the association of two-dimensional echocardiographically-determined LAR and other 
structural and hemodynamic parameters with objective measures of exercise functional 
capacity in 26 patients (14 males, 12 females, mean age=37 years) 
Methods: BSA-normalized left atrial volume by modified Simpson’s biplane method, M- 
mode (MM) and trans-mitral Doppler (E/A ratio) echocardiographic measures were 
obtained in patents undergoing cardiac catheterization within 24 hours of echocardio- 
graphic assessment and correlated with metabolic treadmill stress testing performed dur- 
ing the same admission. Magnetic rescnance imaging (MRI)-determined LV mass was 
also obtained in a subset of 13 subjects. 
Conclusions: Volumetric LAR in HCM patients correlated significantly and consistently 
with metabolic stress testing parameters. LAR predicted objective functional capacity at 
least as well as resting invaswe hemodynamic assessment and was superior to other 
forms of echocardiographic and MRI LV mass assessment 
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Spearman Univariate Correlation Coefficients 
All results are non-significant Maximum VO2 
except as indicated Normalized for 
* p<o.o5 Body Mass 
** p<o.o1 
*** P<O.OOl 
LA Volume-Normalized -0.50” 
Diastolic Septal Thickness (MM) -0.04 
SeptallPosterior Wall Ratio -0.06 
(MM) 
E/A Ratio (Doppler) 0.17 
Left Ventricular Mass (MRI) 0.12 
Pulmonary Artery Systolic -0.50” 
Pressure 
Pulmonary Capillary Wedge -0.50** 
PR?SS”VS 
LV End-Diastolic Pressure -0.30 
Anaerobic Treadmill 
Threshold Exercise Time 
-0.60”’ -0.45” 
0.03 0.06 
-0.11 -0.16 
0.34 0.19 
0.11 -0.37 
-0.27 -0.19 
-0.35 
-0.06 
-0.24 
-0.04 
1014-67 Long-Term Outcome in Patients With Latent 
(Provocable) Obstructive Hypertrophic Cardiomyopathy 
Maria J. Eriksson Anna Woo, E. Douglas Wigle, David Focsaneanu, Paul Rakowski, 
Cairrine Sloggett, Harry Rakowski, Toronto General Hospital, Toronto, ON, Canada 
BACKGROUND: Subaortic obstruction in hypsrtrophic cardiomyopathy (HCM) may be 
classified as obstruction at rest or latent (LO). There is only limited information on long- 
term clinical outcome in HCM patients (pts) presenting with LO. 
METHODS: A retrospective study of 127 pts (73% male) with LOHCM was performed. 
Inclusion criteria were: unexplained left ventricular hypertrophy with no outflow gradient 
(LVOTGR) at rest and ~30 mmHg after provocation, documented by echo (n = 72) or 
catheterization (n = 55). Symptoms, clinical findings, mortality and cardiovascular mar- 
bidity were analyzed. 
RESULTS: The mean age at diagnosis was 45.1 * 15.6 years. At baseline the mean 
LVOTGR at rest was 7+6 mmHg and 64&6 mmHg after provocation. The mean septal 
thickness was 16.5k3.9 mm, with hypertrophy limited to the basal l/3 of septum in 74 pts 
(56%), and to the proximal 2/3 in 37 pts (29%). The mean left atrial diameter was 40*6 
mm. Most common symptoms were dyspnea (33%), chest pain (26%) and pre-lsyncope 
(15%). During a follow-up of 12.6&3 years from diagnosis cardiovascular mortality was 
5.5% (7027) and annual cardiovascular mortality 0.4%, due to sudden cardiac death 
(SCD) (n=4), CHF (n=2) and stroke (n=l). SCD pts had more extensive septal hypertro- 
phy. At 15 years of follow-up survival for LOHCM of 86+4% was not different from that for 
the age- and gender-matched population. Morbid events occurred in 59 pts (46%), the 
most frequent being atrial fibrillation (28%), cerebrovascular events (12%), myocardial 
infarction (9%) and CHF (9%). At the last follow-up pts were on beta-blockers (76%). dis- 
opyramide (19%) or/and calcium channel blockers (19%). Surgical or chemical myec- 
tomy was performed in 14 pts (11%). Seven pts received AICD, for secondary prevention 
(1) and primary prevention (6). Only left atrial enlargement at baseline and older age at 
diagnosis were independent predictors of cardiovascular morbidity. 
CONCLUSION: The majority of pts with LOHCM have less extensive hypertrophy and a 
more favorable prognosis than other types of HCM. However, in the presence of exten- 
sive hypertrophy, left atrial enlargement and older age at diagnosis, LO doss have signif- 
icant cardiovascular morbidity and mortality. 
1014-82 Relation Between Angiotensin-Converting Enzyme II 
Genotype and Cardiovascular Events in Patients With 
Hypettrophic Cardiomyopathy 
Akivoshi Ooimoto, Mareomi Hamada, Jun Nakura, Yuji Shigematsu. Yuji Ham, Tomoaki 
Ohtsuka, Jun Suzuki, Tsuyoshi Matsunaka, Tetsuro Miki, Jitsuo Higaki, Ehime University 
School of Medicine, Ehime, Japan 
Background: The renin-angiotensin system plays a part in the pathophysiology of cardio- 
vascular disease. Many studies showed the benefits of angiotensin converting enzyme 
(ACE) inhibitors in congestive heart failure. However, ACE inhibition in patients with 
hypertrophic cardiomyopathy (HCM) was reported to aggravate hemodynamics and lead 
to hypotension and excessive systolic emptying. The insertion/deletion (I/D) polymor- 
phism of the ACE gene is a marker linked to differences in plasma and cardiac ACE 
activity and an independent risk factor for several heart diseases. Therefore, the purpose 
of this study was to examine the relation between the ACE genotypes and the occur- 
rence of cardiovascular events in patients with HCM. Methods and Results: We geno- 
typed the I/D polymorphism of the ACE gene in genetically independent 151 patients with 
HCM. The cardiovascular events were defined as sudden cardiac death, congestive 
heart failure, thromboembolism. stroke, syncope. atrial fibrillation and sustained ventricu- 
lar tachycardia. Patients with one or more history of the cardiovascular events were 65 
(43%), and patients without history of the cardiovascular events were 66 (57%). Distribu- 
tion of the ACE oenotvoes (DD. ID. and II\ amona the total oatients with HCM was 14%. _ _. _ 
46%. and 40%, respectively. The cardiovascular events were documented in 36% with 
DD. 32% with ID. and 58% with II. Allele freauencv for the I allele was 0.71 in the orouo 
1  ” 
with the cardiovascular events and 0.56 in the other group. There was a significant differ- 
ence in genotypes between the two groups by chi-square test (PcO.01). The odds of the 
cardiovascular events was 3.1.fold higher in patients with the II genotype than in the 
other genotypes. Conclusion: These findings suggest that the II genotype of the ACE 
gene IS a significant risk factor for the cardiovascular events in patients with HCM. 
1014-83 Reduction in Mitral Regurgitation After Alcohol Septal 
Ablation in Patients With Hypertrophic Obstructive 
Cardiomyopathy 
Fred A. Crawford. Ill, Christopher Nielsen, Valerian Fernandes, Mary Frankis, Willlam H. 
Spencer, Ill, Medical University of South Carolina, Charleston, SC 
Background: Mitral Regurgitation (MR) is a common finding in patients with hyper- 
trophic obstructive cardiomyopathy (HOCM). This is thought to be related to systolic 
anterior motion of the mitral valve. Improvements in MR have been documented in paral- 
lel with reduction in left ventricular outflow tract (LVOT) gradient with both dual chamber 
pacing and with surgical myectomy. In this study, we examined reduction in MR and 
associated changes in LVOT gradient and treadmill exercise time before and after alco- 
hol septal ablation. Methods: We reviewed transthoracic echocardiograms from 40 
patients who underwent alcohol septal ablations periormed at our institution. Echocardio- 
grams were done before the procedure and in follow-up 3 months after the procedure. In 
addition to measuring LVOT gradient and treadmill exercrse time, we assessed degree of 
MR by measuring the area of color flow regurgitant jet, ratio of color flow regurgitant jet 
ares to left atrial area, and the peak mitral inflow E velocity. 
Results: At baseline, 39 of 40 patients had MR as measured by color flow doppler. 
There was a significant reduction in MR measured by transthoracic echocardiography at 
3 months follow-up. The pre-procedure mean mitral regurgitant jet area was 5.0 cm2. 
This decreased to 2.1 cm2 at 3 months follow-up (pcO.001). The pre-procedure mean 
mitral regurgitant jet area/ left atrial area was 0.36. This decreased to 0.20 at 3 months 
follow-up (p<O.OOl). The pre-procedure mean peak mitral inflow E velocity was 0.67 m/s. 
This decreased to 0.79 m/s at 3 months follow-up (~~0.05). The pre-procedure mean 
LVOT gradient was 65.6 mm Hg. This decreased to 26.3 mm Hg at 3 months follow-up 
(p<O.OOl). The pre-procedure mean treadmill exercise time was 233.1 seconds. This 
increased to 361.0 seconds at 3 months follow-up (p<O.OOl). Conclusions: Alcohol sep- 
tal ablation results in improved LVOT gradient and treadmill exercise time in patients with 
HOCM. This is associated with a significant reduction in MR. The reduction in MR may 
be an independent contributing factor to the improvement in exercise time and symptoms 
noted in these patients. 
1014-84 Noninvasive Assessment of Coronary Flow Velocity 
Reserve Impairment in Patients With Hypertrophic 
Cardiomyopathy 
Massimo Ruscazio, Roberta Montisci, Maurizio Porcu, Rosa Manzi, Luisella Pistis, 
Norma Zedda, Sabino Iliceto, Luigi Meloni, University of Cagliari, Cagliari, Italy, 
University of Padua, Padua, Italy 
Background.Microvascular impairment occurs frequently in hyperlrophic cardiomyopathy 
patients (HCM), often without evidence of coronary artery stenosis but with impairment of 
coronary flow velocity reserve (CFVR). We tested the hypothesis that CFVR, noninvasive 
monitored, can be impaired in HCM and could be related to the severity of cardiac hyper- 
trophy. 
Methods. We studied 16 HCM (13 males and 5 females), mean age 51 years (range 
16*72 years) and 21 control group patients. We evaluated CFVR in the left anterior 
descending coronary artery (LAD) with contrast enhanced transthoracic Doppler (CE- 
TTE) during adenosine infusion. The pulsed wave Doppler of blood flow velocity was 
recorded in the LAD at rest and after maximum vasodilation by adenosine infusion 
(140[mu]g/KgJmin in 5 minutes). 
Results. In HCM, CFVR was impaired compared to control group (2.3*0.66 Versus 
3.29eO.53 , pcO.001). A significantly, greater percentage of HCM had severe reduction of 
CFVR (~2.0) compared to control group (E/16,44% Versus O/21,0%, p=O.OOl). Diastolic 
mean velocity at rest was significantly higher in HCM with reduced CFVR compared both 
to control group (56.5t16.5 Versus 32.6i15.5 cm/set, pcO.01) and to HCM with normal 
CFVR (56.5+16.5 Versus 31.9i6.5 cm/set, p<O.Ol). However, diastolic mean velocity 
during hyperemia was not statistically different between the 2 groups (92526 Versus 
102+30 cmisec, p=ns) but in HCM with reduced CFVR it was statistically lower when 
compared to both control group (76.2e22.5 Versus 102+30.4 cmisec, ~~0.05 ) and HCM 
with normal CFR (76.2i22.5 Versus 104.5e30.4, ~~0.05 ).Furthermore, HCM with 
greater cardiac hypertrophy (>20 mm) had CFVR severely reduced in comparison to 
HCM with less degree of myocardial involvement (2.0*0.6 Versus 2.6i0.6, pcO.05). 
Conclusion. This study demonstrated that in HCM. CFVR is significantly impaired 
because of increased baseline resting diastolic mean velocity resulting in a reduced 
vasodilatatory capacity and CFVR impawment is related to the degree of cardiac hyper- 
trophy. Noninvasive CEE-TTE assessment of CFVR, could be a simple and reliable 
method in detecting and monitoring microcirculatory dysfunction in HCM. 
1014-85 Injury Size and Location induced by Percutaneous 
Transluminal Septal Myocardial Ablation in 
liypertrophic Obstructive Cardiomyopathy: Effect on 
Gradient Reduction 
Willem G. van Dockum, Folkeri J. ten Gate, Jurrien M. ten Berg, Aernout M. Beek, 
Jeroen Vos. Mark B. Hofman. Cees A. Visser. Alberl C. van Rossum, VU Universitv 
Medical Center, Amsterdam, The Netherlands 
Background: Percutaneous transluminal septal myocardial ablation (PTSMA) reduces 
left ventricular outflow tract (LVOT) obstruction in patients with symptomatic hypertrophic 
obstructive cardiomyopathy (HOCM). The purpose of the study was to evaluate by con- 
trast-enhanced magnetic resonance imaging (MRI) the effect of myocardial injury size 
and location induced by PTSMA on LVOT gradient reduction. 
Methods: Twenty-four patients (age 52+ 15 years) underwent contrast-enhanced (gado- 
linium-DTPA) MRI 1 month after PTSMA for assessment of PTSMA Induced myocardial 
injury size. Location of hyperenhanced myocardium was compared with ethanol infused 
target septal branch, site of balloon inflation and the volume of alcohol administered. 
